|
|
39 Old Ridgebury Road, Suite 11
Danbury, CT 6810 USA
phone:203-796-3700
fax:(203) 794-1393
|
|
| Symbol |
PPCO |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.penw.com/
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Penwest develops pharmaceutical products based on the application of oral drug delivery technologies. |
|
| Management |
| Jennifer L. Good, President and Chief Executive Officer; Benjamin Palleiko, Senior Vice President, Corporate Development and Chief Financial Officer; Mehrdad Abedin, Vice President, Information Technology and Chief Information Officer; Anand R. Baichwal, Ph.D., Sr. Vice President Licensing and Chief Scientific Officer; Philip A. Goliber, Ph.D, Vice President, Pharmaceutical R&D; Paul Hayes, Vice President, Strategic Marketing; Thomas R. Sciascia, M.D., Senior Vice President & Chief Medical Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| drug delivery, oral controlled release, DrugDelivery |
|
|
|
| Description |
|
Penwest develops pharmaceutical products based on the application of innovative oral drug delivery technologies. The foundation of their technology platform is TIMERxÆ, an extended release delivery system that is adaptable to soluble and insoluble drugs and that is flexible providing a variety of controlled release profiles. They have also developed two additional oral drug delivery systems, GeminexÆ and SyncroDoseô. |
|
| Products / Services |
TIMERx, Geminex and SyncroDose.
|
|
| Technology / Differentiation |
| The TIMERx oral controlled release delivery system allows Penwest to modify the release of drugs to provide a therapeutic benefit to patients by delivering medicines that are more efficacious and provide greater patient compliance. The technology is cost-effective and easy to scale-up and manufacture. Geminex is a unique bi-layer, dual-release tablet technology that can deliver two different and unique release profiles for one or more drugs. SyncroDose offers a variety of predetermined lag times, that can control when and where a drug is released, followed by a variety of customized drug-release profiles to include immediate and controlled release. |
|
|
| Strategy |
The overall goal of Penwests product development portfolio is to build a strong pipeline of products in which drug delivery can improve compliance and offer clinical benefits.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
